Rare Case of Oncocytic Carcinoma of Thyroid: Successful Surgical Management of a Large 20 Cm Tumor
DOI:
https://doi.org/10.22376/ijtos.2025.3.1.48-51Keywords:
Hürthle cell carcinoma, Oncocytic carcinoma, Thyroidectomy, Large tumorAbstract
Oncocytic carcinoma of the thyroid (OTC), also known as Hürthle cell carcinoma (HCC), is an extremely rare diagnosis accounting for 3% to 5% of all thyroid cancers. Historically, Hürthle cell carcinoma was considered as a variant of follicular carcinoma because of its origin in the follicular epithelium. However, later reports suggested that they are more aggressive, and most cases were found to be refractory to Radioiodine ablation (RAI). The rarity of HCC and the historical overlap with follicular thyroid cancer has made it difficult to develop Hürthle cell carcinoma-specific management strategies. Management varies based on tumor size and extent, with total thyroidectomy being recommended for larger tumors. The role of radioactive iodine therapy remains controversial. In this report, we present a 71-year-old female who presented to our hospital with a massive (20 cm) thyroid tumor that was diagnosed as oncocytic carcinoma of the thyroid and was successfully managed with total thyroidectomy.
References
Trends in thyroid cancer incidence in Sweden, 1958-1981, by histopathologic type. Pettersson B, Adami HO, Wilander E, Coleman MP. Int J Cancer. 1991;48:28–33. doi: 10.1002/ijc.2910480106.
Hürthle cell carcinoma: current perspectives. Ahmadi S, Stang M, Jiang XS, Sosa JA. Onco Targets Ther. 2016;9:6873–6884. doi: 10.2147/OTT.S119980.
Survival and prognosis in Hürthle cell carcinoma of the thyroid gland. Bhattacharyya N. Arch Otolaryngol Head Neck Surg. 2003;129:207–210. doi: 10.1001/archotol.129.2.207.
Combined tall cell carcinoma and Hürthle cell carcinoma (collision tumor) of the thyroid. Baloch ZW, Mandel S, LiVolsi VA. Arch Pathol Lab Med. 2001;125:541–543. doi: 10.5858/2001-125-0541-CTCCAH.
Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O. Overview of the 2022 WHO classification of thyroid neoplasms. Endocrine pathology. 2022 Mar;33(1):27-63.
Gopal RK, Kübler K, Calvo SE, Polak P, Livitz D, Rosebrock D, Sadow PM, Campbell B, Donovan SE, Amin S, Gigliotti BJ. Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hürthle cell carcinoma. Cancer Cell. 2018 Aug 13;34(2):242-55.
Auger M. Hürthle cells in fine‐needle aspirates of the thyroid: A review of their diagnostic criteria and significance. Cancer cytopathology. 2014 Apr;122(4):241-9.
Alaedeen DI, Khiyami A, McHenry CR. Fine-needle aspiration biopsy specimen with a predominance of Hürthle cells: a dilemma in the management of nodular thyroid disease. Surgery. 2005 Oct 1;138(4):650-7.
Yi JW, Park JY, Sung JY, Kwak SH, Yu J, Chang JH, Kim JH, Ha SY, Paik EK, Lee WS, Kim SJ. Genomic evidence of reactive oxygen species elevation in papillary thyroid carcinoma with Hashimoto thyroiditis. Endocrine journal. 2015;62(10):857-77.
Guerin C, Taieb D, Treglia G, Brue T, Lacroix A, Sebag F, Castinetti F. Bilateral adrenalectomy in the 21st century: when to use it for hypercortisolism?. Endocrine-Related Cancer. 2016 Feb 1;23(2):R131-42.
Lukovic J, Petrovic I, Liu Z, Armstrong SM, Brierley JD, Tsang R, Pasternak JD, Gomez-Hernandez K, Liu A, Asa SL, Mete O. Oncocytic papillary thyroid carcinoma and oncocytic poorly differentiated thyroid carcinoma: clinical features, uptake, and response to radioactive iodine therapy, and outcome. Frontiers in Endocrinology. 2021 Dec 16;12:795184.
Li X, An B, Ma J, He B, Qi J, Wang W, Qin C, Zhao Q. Prognostic value of the tumor size in resectable colorectal cancer with different primary locations: a retrospective study with the propensity score matching. Journal of Cancer. 2019;10(2):313.
Bello HR, Mahdi ZK, Lui SK, Nandwana SB, Harri PA, Davarpanah AH. Hepatocellular carcinoma with atypical imaging features: review of the morphologic hepatocellular carcinoma subtypes with radiology‐pathology correlation. Journal of Magnetic Resonance Imaging. 2022 Mar;55(3):681-97.
Canberk S, Lima AR, Pinto M, Soares P, Máximo V. Epigenomics in Hürthle cell neoplasms: filling in the gaps towards clinical application. Frontiers in Endocrinology. 2021 May 24;12:674666.
Klain M, Nappi C, Zampella E, Cantoni V, Green R, Piscopo L, Volpe F, Manganelli M, Caiazzo E, Petretta M, Schlumberger M. Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging. 2021 Dec;48(13):4437-44.
Julsrud TO, Foster TR, Vierkant RA, Lyden ML, McKenzie TJ, Ryder M, Dy BM. Hürthle cell (Oncocytic) carcinoma–Is hemithyroidectomy enough?. Surgical Oncology Insight. 2024 Mar 1;1(1):100010.
Huang TY, Wang CY, Chen KY, Huang LT. Urinary exosomal thyroglobulin in thyroid cancer patients with post-ablative therapy: a new biomarker in thyroid cancer. Frontiers in Endocrinology. 2020 Jun 16;11:382.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Dr. Govindaraj Vardhanan, Dr. Ponniah Sasipriya, Dr. Gunasekaran, Dr. A. Mallika, Dr. Hareni Murugavel
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
